Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men

• Published in: Prostate cancer and prostatic diseases Vol. 20; no. 3; pp. 348 - 351
• Main Authors: Kongnyuy, M, Siddiqui, M M, George, A K, Muthigi, A, Sidana, A, Maruf, M, Turkbey, B, Choyke, P L, Wood, B J, Pinto, P A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.09.2017; Nature Publishing Group
• Subjects: 631/67/2324; 692/699/67/589/466; African Americans; Aged; Biomedical and Life Sciences; Biomedicine; Biopsy; Cancer; Cancer Research; Categories; Chi-square test; Demographic variables; Demographics; Demography; Diagnosis; Diagnostic Errors; George, Kallie; Health aspects; Health risks; Humans; Image-Guided Biopsy; Magnetic Resonance Imaging; Male; Medical imaging; Medical research; Medicine, Experimental; Men; Methods; Middle Aged; NMR; Nuclear magnetic resonance; original-article; Patient outcomes; Patients; Prostate - diagnostic imaging; Prostate - pathology; Prostate cancer; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - pathology; Risk; Statistical analysis; Statistical tests; Ultrasonic imaging; Ultrasonography; Ultrasound; Ultrasound imaging
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/pcan.2017.21

Background: Analysis of systematic 12-core biopsies (SBx) has shown that African-American (AA) men tend to harbor higher risk prostate cancer (PCa) at presentation relative to other races. Multiparametric magnetic resonance imaging (mpMRI) and MRI-ultrasound fusion-guided biopsy (FBx) have been shown to diagnose more intermediate- and high-risk PCa in the general population; however, the efficacy in AA remains largely uncharacterized. We aim to evaluate the utility of FBx in an AA patient cohort. Methods: Men suspected of PCa underwent an mpMRI and FBx with concurrent SBx from 2007 to 2015 in this institutional review board-approved prospective cohort study. Patient demographics, imaging and fusion biopsy variables were collected. χ 2 , Mann–Whitney U -test and McNemar’s tests were performed to compare proportions, means and paired variables, respectively. Clinically significant PCa (CSPCa) was defined as Gleason score ⩾3+4. Results: Fusion biopsy demonstrated exact agreement with SBx risk categories in 64% of AA men. There was no statistically significant difference in the detection of CSPCa between FBx vs SBx (68 vs 62 cases, P =0.36). However, FBx detected 41% fewer cases of clinically insignificant PCa (CIPCa) compared with SBx (FBx 30 vs SBx 51 cases, P =0.0004). The combined FBx/SBx biopsy approach detected significantly more cases of CSPCa (FBx/SBx 80 vs SBx 62 cases, P =0.004) while detecting comparable number of cases of CIPCa (FBx/SBx 45 vs SBx 51 cases, P =0.37) compared with SBx alone. FBx/SBx also detected more CSPCa in patients with a history of prior negative SBx (FBx/SBx 28 vs 19 cases, P =0.003). Conclusions: FBx when used in combination with SBx detected more cases of CSPCa while not significantly increasing the diagnosis of CIPCa in AA men. Future multicenter studies will be needed to validate ultimately the clinical implications of FBx in AA patients.